Why Norgine’s PEDMARQSI approval in Switzerland could reshape cisplatin ototoxicity management

Swissmedic approved PEDMARQSI for cisplatin-related hearing loss in children. Read why this could reshape paediatric oncology supportive care.

Swissmedic approved PEDMARQSI for cisplatin-related hearing loss in children. Read why this could reshape paediatric oncology supportive care.